ATE244763T1 - Erzielen von homozygotem durch zielgerichtete genetische ereignisse - Google Patents

Erzielen von homozygotem durch zielgerichtete genetische ereignisse

Info

Publication number
ATE244763T1
ATE244763T1 AT93905784T AT93905784T ATE244763T1 AT E244763 T1 ATE244763 T1 AT E244763T1 AT 93905784 T AT93905784 T AT 93905784T AT 93905784 T AT93905784 T AT 93905784T AT E244763 T1 ATE244763 T1 AT E244763T1
Authority
AT
Austria
Prior art keywords
homozygote
achievement
marker gene
targeted genetic
genetic events
Prior art date
Application number
AT93905784T
Other languages
English (en)
Inventor
Jonathan G Seidman
Aya Jakobovits
Original Assignee
Cell Genesys Inc
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc, Harvard College filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of ATE244763T1 publication Critical patent/ATE244763T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
AT93905784T 1992-02-11 1993-02-02 Erzielen von homozygotem durch zielgerichtete genetische ereignisse ATE244763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83399292A 1992-02-11 1992-02-11
PCT/US1993/000926 WO1993016177A1 (en) 1992-02-11 1993-02-02 Homogenotization of gene-targeting events

Publications (1)

Publication Number Publication Date
ATE244763T1 true ATE244763T1 (de) 2003-07-15

Family

ID=25265825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93905784T ATE244763T1 (de) 1992-02-11 1993-02-02 Erzielen von homozygotem durch zielgerichtete genetische ereignisse

Country Status (7)

Country Link
US (1) US5589369A (de)
EP (1) EP0626012B1 (de)
JP (1) JP3571337B2 (de)
AT (1) ATE244763T1 (de)
CA (1) CA2128862C (de)
DE (1) DE69333082T2 (de)
WO (1) WO1993016177A1 (de)

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1992020808A1 (en) * 1991-05-15 1992-11-26 Cell Genesys, Inc. Genomic modifications with homologous dna targeting
US20020108136A1 (en) * 1997-03-21 2002-08-08 Sri Transgenic animals produced by homologous sequence targeting
DE69425903T2 (de) * 1993-12-09 2001-02-15 Thomas Jefferson University Ph Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US5731181A (en) * 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
US6924146B1 (en) * 1997-02-21 2005-08-02 Sigrid Wattler Method of constructing vectors for homologous recombination directed mutagenesis
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
SI1787999T1 (sl) 1997-04-07 2010-12-31 Genentech Inc Anti-VEGF protitelesa
US6194633B1 (en) 1998-01-26 2001-02-27 University Of Iowa Research Foundation Non-human animal having a functionally disrupted SLP-76 gene
US7820161B1 (en) 1999-05-07 2010-10-26 Biogen Idec, Inc. Treatment of autoimmune diseases
DE60042066D1 (de) 1999-05-28 2009-06-04 Genentech Inc Chimärische dr4 antikörper und ihre verwendung
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
EP2283867B1 (de) 1999-06-25 2014-05-21 ImmunoGen, Inc. Methoden zur behandlung unter verwendung von erb antibody-mayntasinoid konjugate
US7217699B2 (en) * 2000-01-03 2007-05-15 Panagenic International, Inc. Compositions comprising genome segments and methods of using the same
CN100390288C (zh) 2000-04-11 2008-05-28 杰南技术公司 多价抗体及其应用
WO2001088096A2 (en) * 2000-05-15 2001-11-22 Geron Corporation Ovine tissue for xenotransplantation
WO2001097858A2 (en) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
CA2634294A1 (en) * 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
WO2002022834A2 (en) * 2000-09-15 2002-03-21 Deltagen, Inc. Methods of producing cells and animals comprising targeted gene modifications
MXPA03002262A (es) * 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2444661A1 (en) 2001-01-31 2002-08-08 Idec Pharmaceutical Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
WO2002072768A2 (en) * 2001-03-09 2002-09-19 Todd Waldman ISOGENIC ss-CATENIN CELL LINES, AND METHODS OF MAKING AND USING SAME
CA2440676A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
WO2002079255A1 (en) * 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
CA2481515C (en) 2002-04-10 2013-10-01 Genentech, Inc. Anti-her2 antibody variants
NZ537660A (en) 2002-07-15 2008-12-24 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
CA2498264A1 (en) * 2002-09-09 2004-05-13 Nura, Inc. G protein coupled receptors and uses thereof
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
DK1572106T3 (da) 2002-11-15 2010-08-23 Novartis Vaccines & Diagnostic Fremgangsmåde til forebyggelse og behandling af cancermetastase og knogletab forbundet med cancermetastase
EP1585768A2 (de) * 2003-01-23 2005-10-19 Genentech, Inc. Verfahren zur herstellung von menschlischen antikörpern und zur steigerung der ausbeute von antikörpern oder von antigenbindenden fragmenten in zellkultur
HUE025347T2 (en) 2003-03-19 2016-02-29 Biogen Ma Inc NOGO receptor binding protein
MXPA05010778A (es) 2003-04-09 2005-12-12 Genentech Inc Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1629001A2 (de) 2003-06-05 2006-03-01 Genentech, Inc. Blys-antagonisten und deren verwendung
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
PL1704166T3 (pl) 2004-01-07 2015-10-30 Novartis Vaccines & Diagnostics Inc Przeciwciała monoklonalne swoiste względem M-CSF i ich zastosowania
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20060002930A1 (en) * 2004-04-16 2006-01-05 Genentech, Inc. Treatment of disorders
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
EP1753455A2 (de) 2004-06-04 2007-02-21 Genentech, Inc. Verfahren zur behandlung von multipler sklerose
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006055836A2 (en) * 2004-11-16 2006-05-26 President And Fellows Of Harvard College In vivo alteration of cellular dna
EP2311880A3 (de) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto-bindende Moleküle
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
NZ590431A (en) 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
NZ563043A (en) * 2005-05-04 2010-04-30 Tmo Renewables Ltd Thermophilic microorganisms with inactivated lactate dehydrogenase gene (LDH) for ethanol production
GB0511602D0 (en) * 2005-06-07 2005-07-13 Tmo Biotec Ltd Microorganisms
EP2937360A1 (de) * 2005-06-17 2015-10-28 Merck Sharp & Dohme Corp. Ilt3-bindende moleküle und verwendungen davon
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
PT1904104E (pt) 2005-07-08 2013-11-21 Biogen Idec Inc Anticorpos sp35 e suas utilizações
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
WO2007016240A2 (en) * 2005-07-28 2007-02-08 Novartis Ag Use of antibody to m-csf
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
MX2008005764A (es) 2005-11-04 2008-11-18 Biogen Idec Inc Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP2009516513A (ja) * 2005-11-21 2009-04-23 ラボラトワール セローノ ソシエテ アノニム ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用
NZ569428A (en) 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
CN101573441A (zh) * 2005-12-08 2009-11-04 路易斯维尔大学研究基金会有限公司 非常小的胚胎样（vsel）干细胞及分离和利用其的方法
US9155762B2 (en) * 2005-12-08 2015-10-13 University Of Louisville Research Foundation, Inc. Uses and isolation of stem cells from bone marrow
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
DK1981902T3 (en) 2006-01-27 2015-10-05 Biogen Ma Inc Nogo Receptor Antagonists
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
SG170728A1 (en) 2006-03-23 2011-05-30 Novartis Ag Anti-tumor cell antigen antibody therapeutics
US8524454B2 (en) * 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
CN103435697A (zh) 2006-05-15 2013-12-11 航道生物技术有限责任公司 流感病毒的中和抗体
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
AU2007275654A1 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania WSX-1/p28 as a target for anti-inflammatory responses
WO2008019326A2 (en) 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
EP2423231A3 (de) 2006-08-18 2012-05-30 Novartis AG PRLR-spezifischer Antikörper und Anwendung
EP2423333A1 (de) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognosemarker und therapeutische Targets für Lungenkrebs
CN101506235B (zh) 2006-09-01 2012-07-25 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
US20080076139A1 (en) 2006-09-21 2008-03-27 Sharat Singh Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
NZ574635A (en) * 2006-09-28 2011-08-26 Tmo Renewables Ltd Thermophilic microorganisms for ethanol production
RU2460541C2 (ru) 2006-10-27 2012-09-10 Лпат, Инк. Композиции и способы связывания сфингозин-1-фосфата
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US20090155225A1 (en) * 2006-11-02 2009-06-18 Mariusz Ratajczak Uses and isolation of very small of embryonic-like (vsel) stem cells
CA2672120A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonistic antibodies against ephb3
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
WO2008079322A1 (en) * 2006-12-22 2008-07-03 Beckman Coulter, Inc. Methods, kits and materials for diagnosing disease states by measuring isoforms or proforms of myeloperoxidase
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
SI2068887T1 (sl) 2007-01-09 2014-06-30 Biogen Idec Ma Inc. SP35 protitelesa in njihova uporaba
EP2111412A2 (de) 2007-02-02 2009-10-28 Amgen, Inc Hepcidin und hepcidin-antikörper
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
AU2008239633B2 (en) 2007-04-12 2014-05-29 The Brigham And Women's Hospital, Inc. Targeting ABCB5 for cancer therapy
JP5989299B2 (ja) * 2007-05-30 2016-09-07 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． リゾホスファチジン酸結合のための組成物と方法
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
TWI478939B (zh) 2007-06-15 2015-04-01 Deutsches Krebsforsch 使用特定抗－ｌ１抗體治療腫瘤
CA2693677C (en) * 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
GB0715751D0 (en) 2007-08-13 2007-09-19 Tmo Renewables Ltd Thermophilic micro-organisms for ethanol production
KR20100075857A (ko) 2007-08-24 2010-07-05 온코세라피 사이언스 가부시키가이샤 폐암의 치료 및 진단의 표적유전자인 ｅｂｉ３，ｄｌｘ５，ｎｐｔｘ１ 및 ｃｄｋｎ
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
CN101970689A (zh) 2007-11-29 2011-02-09 健泰科生物技术公司 炎性肠病的基因表达标志物
EP2391650B1 (de) 2007-12-20 2014-10-15 Xoma (Us) Llc Verfahren zur behandlung von gicht
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
EP2274334A2 (de) 2008-03-28 2011-01-19 Sea Lane Biotechnologies,llc. Neutralisierende moleküle gegen virale antigene
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
MX2010011717A (es) 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
EP2315779A2 (de) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
EP2323679A4 (de) 2008-07-25 2012-08-22 Univ Colorado Clip-hemmer und verfahren zur modulierung der immunfunktion
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
GB0820262D0 (en) 2008-11-05 2008-12-10 Tmo Renewables Ltd Microorganisms
CA2745436A1 (en) * 2008-12-05 2010-06-10 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP2376117A1 (de) 2008-12-17 2011-10-19 Genentech, Inc. Hepatitis-c-virus-kombinationstherapie
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
AU2010276392A1 (en) 2009-07-20 2012-03-08 Genentech, Inc. Gene expression markers for Crohn's disease
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
EP2491385B1 (de) 2009-10-20 2017-05-10 DiaTech Holdings, Inc. Proximitätsvermittelte tests für den nachweis von onkogenen fusionsproteinen
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
BR112012029904A2 (pt) 2010-05-25 2017-08-08 Genentech Inc métodos de purificação de polipeptídeos
CA2804280A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Chimeric clotting factors
JP2013535692A (ja) 2010-08-10 2013-09-12 アムジエン・インコーポレーテツド 標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ
KR20130110169A (ko) 2010-09-22 2013-10-08 암젠 인크 담체 면역글로뷸린 및 이것의 용도
TWI603738B (zh) 2010-11-08 2017-11-01 建南德克公司 皮下投予抗－ｉｌ－６受體抗體
US20140199682A1 (en) 2010-11-17 2014-07-17 Sea Lane Biotechnologies, Llc Influenza neutralizing agents
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
BR112013013083A2 (pt) 2010-11-30 2016-12-13 Genentech Inc métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
WO2012075333A2 (en) 2010-12-02 2012-06-07 Prometheus Laboratories Inc. Her2delta16 peptides
SG191230A1 (en) 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
KR102577578B1 (ko) 2011-06-03 2023-09-11 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
JP6186575B2 (ja) 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
US20140301977A1 (en) 2011-11-02 2014-10-09 Genentech, Inc. Overload and elute chromatography
EP3050900A1 (de) 2011-12-19 2016-08-03 Xoma (Us) Llc Verfahren zur behandlung von akne
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
PT2802606T (pt) 2012-01-10 2018-07-13 Biogen Ma Inc Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica
CA2864702A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
AU2013262611B2 (en) 2012-05-18 2018-03-01 Genentech, Inc. High-concentration monoclonal antibody formulations
SG11201407669QA (en) 2012-05-21 2014-12-30 Genentech Inc Methods for improving safety of blood-brain barrier transport
EP2859017B1 (de) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
AU2013307406B2 (en) 2012-08-29 2018-03-15 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
WO2014078729A1 (en) 2012-11-15 2014-05-22 Genentech, Inc. IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
UA119235C2 (uk) 2013-05-20 2019-05-27 Дженентек, Інк. Антитіло анти-рецептор трансферину і способи його застосування
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
PL3019516T3 (pl) 2013-07-12 2019-04-30 Hoffmann La Roche Objaśnienie optymalizacji wprowadzania w chromatografii jonowymiennej
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
CA2922832A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
CN111732652A (zh) 2013-09-09 2020-10-02 卡尼姆盖德治疗学公司 免疫系统调节器
KR102373930B1 (ko) 2013-09-13 2022-03-11 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
WO2015048331A1 (en) 2013-09-25 2015-04-02 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
EP3062884B1 (de) 2013-10-29 2020-12-02 President and Fellows of Harvard College Zusammensetzungen zur verwendung in der behandlung von retinitis pigmentosa
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
ES2753551T3 (es) 2014-07-22 2020-04-13 Sutro Biopharma Inc Anticuerpos anti-cd74, composiciones que comprenden anticuerpos anti-CD74 y procedimientos de uso de los anticuerpos anti-CD74
CA2964313C (en) 2014-10-15 2023-03-14 Amgen Inc. Promoter and regulatory elements for improved expression of heterologous genes in host cells
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
EP3221362B1 (de) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
JP2018502840A (ja) 2014-12-10 2018-02-01 ジェネンテック， インコーポレイテッド 血液脳関門受容体抗体及び使用方法
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
AU2016229309B2 (en) 2015-03-06 2021-12-02 Canimguide Therapeutics Ab Immune system modulators and compositions
EP3770171A1 (de) 2015-04-03 2021-01-27 XOMA Technology Ltd. Behandlung von krebs unter verwendung von inhibitoren von tgf-beta und pd-1
SG10201911335TA (en) 2015-05-28 2020-01-30 Genentech Inc Cell-based assay for detecting anti-cd3 homodimers
JP6884111B2 (ja) 2015-05-29 2021-06-09 ジェネンテック， インコーポレイテッド 癌におけるｐｄ−ｌ１プロモーターのメチル化
AU2016304588A1 (en) 2015-08-06 2018-02-15 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
CN108431038A (zh) 2015-10-06 2018-08-21 豪夫迈·罗氏有限公司 治疗多发性硬化的方法
EP3377533A2 (de) 2015-11-19 2018-09-26 Sutro Biopharma, Inc. Anti-lag3-antikörper, zusammensetzungen mit anti-lag3-antikörpern und verfahren zur verwendung von anti-lag3-antikörpern
CN109073635A (zh) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
US10519250B2 (en) 2016-08-01 2019-12-31 Xoma (Us) Llc Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
KR102617148B1 (ko) 2016-08-15 2023-12-26 제넨테크, 인크. 비이온성 계면활성제 및 폴리펩티드를 포함하는 조성물에서 비이온성 계면활성제를 정량화하기 위한 크로마토그래피 방법
MX2019003543A (es) 2016-09-28 2019-06-17 Xoma Us Llc Anticuerpos que se fijan al interleucina-2 y sus usos.
WO2018071597A1 (en) 2016-10-12 2018-04-19 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2018156777A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018217940A2 (en) 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP3658588A1 (de) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
MX2020000957A (es) 2017-07-26 2020-07-22 Forty Seven Inc Anticuerpos anti-sirp-alfa y metodos relacionados.
WO2019055909A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
SG11202006400UA (en) 2018-01-04 2020-08-28 Iconic Therapeutics Inc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
US11993658B2 (en) 2018-03-26 2024-05-28 Sutro Biopharma, Inc. Anti-BCMA antibodies and treatment methods
EP3774916A2 (de) 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin-33-wirkstoffe und -zusammensetzungen und verfahren zur herstellung und verwendung davon
JP2022500454A (ja) 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体抗体コンジュゲートによる併用療法
EP3856343A1 (de) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
JP2022502052A (ja) 2018-09-27 2022-01-11 ティゾナ セラピューティクス 抗ｈｌａ−ｇ抗体、抗ｈｌａ−ｇ抗体を含む組成物、および抗ｈｌａ−ｇ抗体を使用する方法
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
CN114072423A (zh) 2019-02-21 2022-02-18 翠舒拉治疗股份有限公司 涉及抗cd39抗体和抗pd-1或抗pd-l1抗体的组合疗法
JP2022528804A (ja) 2019-04-18 2022-06-15 ジェネンテック， インコーポレイテッド 抗体力価試験
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
AU2020270407A1 (en) 2019-05-03 2021-12-02 Celgene Corporation Anti-BCMA antibody conjugate, compositions comprising the same, and methods of making and using the same
WO2020232262A1 (en) 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
EP3821250B1 (de) 2019-05-16 2022-05-04 ProciseDx Inc. Testverfahren zum nachweis von vcam-1 und alpha-2-makroglobulin in blut
WO2020236528A1 (en) 2019-05-23 2020-11-26 Procisedx Inc. Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
JP2022535125A (ja) 2019-06-06 2022-08-04 プロサイセデクス インコーポレイティド 血中ヘモグロビンＡ１Ｃ（ＨｂＡ１ｃ）の検出
CN114269749A (zh) 2019-06-10 2022-04-01 苏特罗生物制药公司 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
JP2022536800A (ja) 2019-06-17 2022-08-18 ストロ バイオファーマ インコーポレーテッド Ｔｏｌｌ様受容体（ｔｌｒ）７／８アゴニストとしての１－（４－（アミノメチル）ベンジル）－２－ブチル－２ｈ－ピラゾロ［３，４－ｃ］キノリン－４－アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
WO2020263450A1 (en) 2019-06-25 2020-12-30 Procisedx Inc. Detection of anti-tnf alpha drug biologics and anti-drug antibodies
EP4090681A1 (de) 2020-01-17 2022-11-23 Biolegend, Inc. Anti-tlr7-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
CN115916820A (zh) 2020-03-23 2023-04-04 基因泰克公司 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
JP2023518812A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ
CN115867577A (zh) 2020-03-23 2023-03-28 基因泰克公司 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
WO2021222533A1 (en) 2020-04-30 2021-11-04 Procisedx Inc. Methods of detecting antibodies to sars-cov-2
JP2023531678A (ja) 2020-06-22 2023-07-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 加齢筋肉、萎縮性筋肉、または異栄養性筋肉の処置のためのｔｓｐ－１阻害物質
US20230357418A1 (en) 2020-09-17 2023-11-09 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
AR125490A1 (es) 2021-04-30 2023-07-19 Celgene Corp Terapias de combinación que utilizan un anticuerpo anti-bcma conjugado a fármaco (adc) en combinación con un inhibidor de gamma secretasa (gsi)
EP4340876A1 (de) 2021-05-19 2024-03-27 Sutro Biopharma, Inc. Kombinationstherapie mit anti-folat-rezeptorkonjugaten mit bevacizumab
KR20240019831A (ko) 2021-06-11 2024-02-14 제넨테크, 인크. St2 길항제를 이용하여 만성 폐쇄성 폐질환을 치료하는 방법
WO2023028501A1 (en) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
WO2023102077A1 (en) 2021-12-01 2023-06-08 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
WO2023104904A2 (en) 2021-12-08 2023-06-15 Genclis The sars-cov-2 and variants use two independent cell receptors to replicate
US20230364020A1 (en) 2022-04-01 2023-11-16 Genentech, Inc. Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
WO2023245105A1 (en) 2022-06-17 2023-12-21 Genentech, Inc. Use of kosmotropes to enhance yield of an affinity chromatography purification step
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA

Also Published As

Publication number Publication date
DE69333082D1 (de) 2003-08-14
WO1993016177A1 (en) 1993-08-19
JP3571337B2 (ja) 2004-09-29
CA2128862C (en) 2008-05-20
DE69333082T2 (de) 2004-05-06
EP0626012A1 (de) 1994-11-30
US5589369A (en) 1996-12-31
JPH07503848A (ja) 1995-04-27
EP0626012A4 (en) 1996-01-03
EP0626012B1 (de) 2003-07-09
CA2128862A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
ATE244763T1 (de) Erzielen von homozygotem durch zielgerichtete genetische ereignisse
Clark Invasion and maintenance of a gene duplication.
DK1032680T3 (da) En hidtil ukendt metode til integration af fremmed DNA ind i eukaryote genomer
Hastings Stable cycling in discrete-time genetic models.
DE69427997D1 (de) Hybrider mensch/tier faktor viii
Szymura et al. Concordant change in mitochondrial and nuclear genes in a hybrid zone between two frog species (genus Bombina)
DK0724639T3 (da) Fremgangsmåder til udvælgelse af rekombinante værtsceller, der udtrykker høje niveauer af et ønsket protein
DK0731845T3 (da) Homologt rekombinant antistofekspressionssystem til murine celler
Wu et al. Mitochondrial‐encoded endonucleases drive recombination of protein‐coding genes in yeast
Smith et al. Gene conversion shapes linear mitochondrial genome architecture
DE69635955D1 (de) Verbesserter einbau exogener dna in pflanzenzellen
DE69033961T2 (de) Zellinien, die einen biologisch aktiven faktor-ix exprimieren
SE8104700L (sv) Eukaryotiskt autonomt replikerande segment
Karlin et al. Allo-allo-triploid Sphagnum× falcatulum: single individuals contain most of the Holantarctic diversity for ancestrally indicative markers
Cummings Extrachromosomal DNA
AU2002252984A1 (en) Stress resistance as a selectable marker for transgenic plants
WO2002010364A3 (en) Methods for enhancing targeted gene alteration using oligonucleotides
Mlinarec et al. Structure and Methylation of 35S rDNA in Allopolyploids Anemone multifida (2 n= 4 x= 32, BBDD) and Anemone baldensis (2 n= 6 x= 48, AABBDD) and Their Parental Species Show Evidence of Nucleolar Dominance
DK0436007T3 (da) Fremgangsmåde til stedspecifik integration af DNA i planters genom.
ATE265523T1 (de) Prokaryontische zelle, die zwei kopien eines genes enthält, die in zwei verschiedene richtungen transkribiert werden.
AU5804099A (en) Geminivirus resistant transgenic plants
WO2000054573A8 (en) Geminivirus resistant transgenic plants
Il'ina Structural organization and mechanisms of mobility of the gene cassettes encoding bacterial antibiotic resistance and virulence factors
Wöhrmann et al. The population biological consequences of a mosaic-like population structure in Macrosiphum rosae.
Hecht The role of natural selection and evolutionary rates in the evolution of higher levels of organization

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties